Deutsche Bank Aktiengesellschaft Increases R1 RCM (NASDAQ:RCM) Price Target to $16.00

R1 RCM (NASDAQ:RCM) had its price objective hoisted by Deutsche Bank Aktiengesellschaft from $14.00 to $16.00 in a research report released on Tuesday morning, Benzinga reports. The firm currently has a hold rating on the healthcare provider’s stock.

A number of other research analysts also recently issued reports on RCM. KeyCorp restated a sector weight rating on shares of R1 RCM in a research note on Wednesday, April 10th. Morgan Stanley restated an overweight rating and set a $17.00 price target on shares of R1 RCM in a research note on Monday, July 8th. Royal Bank of Canada restated an outperform rating and set a $19.00 price target on shares of R1 RCM in a research note on Friday, June 28th. Citigroup upgraded R1 RCM from a neutral rating to a buy rating and set a $16.00 price target on the stock in a research note on Wednesday, March 20th. Finally, Truist Financial restated a hold rating and set a $16.00 price target on shares of R1 RCM in a research note on Monday, April 1st. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, R1 RCM presently has a consensus rating of Moderate Buy and an average target price of $16.00.

R1 RCM Trading Up 1.0 %

RCM opened at $12.61 on Tuesday. R1 RCM has a one year low of $8.87 and a one year high of $18.70. The company has a market cap of $5.31 billion, a P/E ratio of -157.63 and a beta of 0.85. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 1.79. The business’s 50-day simple moving average is $12.41 and its 200-day simple moving average is $11.97.

R1 RCM (NASDAQ:RCM) last released its quarterly earnings data on Wednesday, May 8th. The healthcare provider reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). R1 RCM had a negative net margin of 1.39% and a negative return on equity of 1.16%. The business had revenue of $603.90 million during the quarter, compared to analysts’ expectations of $612.88 million. The company’s quarterly revenue was up 10.7% on a year-over-year basis. As a group, equities research analysts expect that R1 RCM will post -0.17 EPS for the current fiscal year.

Hedge Funds Weigh In On R1 RCM

Several hedge funds have recently bought and sold shares of the stock. Advisors Asset Management Inc. purchased a new stake in shares of R1 RCM in the first quarter valued at $27,000. ANTIPODES PARTNERS Ltd grew its position in shares of R1 RCM by 429.5% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,623 shares of the healthcare provider’s stock valued at $59,000 after purchasing an additional 4,561 shares during the period. Salem Investment Counselors Inc. acquired a new position in R1 RCM in the fourth quarter valued at $61,000. Van ECK Associates Corp boosted its holdings in R1 RCM by 20.5% in the fourth quarter. Van ECK Associates Corp now owns 6,141 shares of the healthcare provider’s stock valued at $65,000 after acquiring an additional 1,044 shares during the last quarter. Finally, QRG Capital Management Inc. acquired a new position in R1 RCM in the first quarter valued at $132,000. Hedge funds and other institutional investors own 61.10% of the company’s stock.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.